SRPT Stock Rises 23% in a Year: Time to Buy, Hold or Sell?

SRPT Stock Rises 23% In A Year: Time To Buy, Hold Or Sell?

2 weeks from now

Jan 6, 2025  · Shares of Sarepta Therapeutics SRPT have risen 23% in the past year, significantly outperforming the industry’s 15.7% decline, as shown in the chart below. During this …

yahoo.com

Temporary Revenue Surge And Market Penetration Concerns Lead …

2 weeks from now

21 hours ago  · Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Sell rating on Sarepta Therapeutics (SRPT – Research Report) and keeping the price target at $75.00. Discover …

businessinsider.com

Should I Buy Sarepta Therapeutics (SRPT) - Zacks

2 weeks from now

Jan 8, 2025  · SRPT Stock Rises 23% in a Year: Time to Buy, Hold or Sell? The Zacks Analyst Blog Highlights Sarepta Therapeutics, ADMA... SRPT: What are Zacks experts saying now?

zacks.com

SRPT Price Target - ETF Channel

2 weeks from now

SRPT Stock Rises 23% in a Year: Time to Buy, Hold or Sell? The upside in Sarepta's share price can be attributed to the encouraging sales performance of its DMD gene therapy, which has …

etfchannel.com

Sarepta Maintained At Sell Rating By H.C. Wainwright On 112% Q/Q …

2 weeks from now

21 hours ago  · On Wednesday, H.C. Wainwright analysts reiterated a Sell rating on Sarepta Therapeutics stock (NASDAQ: SRPT). The firm's analysis follows Sarepta's recent pre …

investing.com

SRPT Stock Rises 23% In A Year: Time To Buy, Hold Or Sell?

2 weeks from now

Jan 6, 2025  · Shares of Sarepta Therapeutics SRPT have risen 23% in the past year, significantly outperforming the industry ’s 15.7% decline, as shown in the chart below.

nasdaq.com

Here's Why Sarepta Therapeutics (SRPT) Is A Great 'Buy The

2 weeks from now

Nov 13, 2023  · A downtrend has been apparent in Sarepta Therapeutics (SRPT) lately. While the stock has lost 25.6% over the past two weeks, it could witness a trend reversal as a hammer …

nasdaq.com

ETFs Holding SRPT | Sarepta Therapeutics Inc | ETF Channel

2 weeks from now

SRPT Stock Rises 23% in a Year: Time to Buy, Hold or Sell? The upside in Sarepta's share price can be attributed to the encouraging sales performance of its DMD gene therapy, which has …

etfchannel.com

Sarepta (SRPT) Stock Up 76.8% In Three Months: Here's Why

2 weeks from now

Sep 12, 2022  · Shares of Sarepta Therapeutics SRPT have surged 76.8% in the past three months compared with the industry’s 10.2% rise.

nasdaq.com

SRPT Stock Rises 23% In A Year: Time To Buy, Hold Or Sell?

2 weeks from now

Jan 6, 2025  · Shares of Sarepta Therapeutics (SRPT Quick Quote SRPT - Free Report) have risen 23% in the past year, significantly outperforming the industry’s 15.7% decline, as shown …

zacks.com

What Date Does Sarepta Therapeutics's (SRPT) Report Earnings

2 weeks from now

Jan 8, 2025  · Look out for SRPT's next earnings release expected on February 26, 2025. For the next earning release, we expect the company to report earnings of $1.38 per share, reflecting …

zacks.com

118.43 SRPT - Sarepta Therapeutics Inc Stock Price Forecast

2 weeks from now

In 2028, Sarepta Therapeutics Inc (SRPT) is projected to reach an average price of $ 139.33, with a high projection of $ 169.23 and a low estimate of $ 109.42. This indicates an +17.64% rise …

stockscan.io

Goldman Sachs Full-Year Profit Rises 68% - Yahoo

2 weeks from now

8 hours ago  · Goldman Sachs drove $14.28 billion of profit in 2024, up 68% from the year earlier, reflecting gains in investment banking and trading. Net income in the fourth quarter rose from …

yahoo.com

Angi Stock Rises After IAC Spinoff News - Yahoo

2 weeks from now

1 day ago  · Shares of Angi rose 16% in after-hours trading Monday following the announcement that media and internet holding company IAC is spinning off its stake in the home-services …

yahoo.com

Atlassian Stock Rises 24% In 3 Months: What Should Investors Do?

2 weeks from now

1 day ago  · Atlassian currently carries a Zacks Rank #3 (Hold), implying that existing investors should hold the stock while new buyers should wait for a better entry point into the stock.

yahoo.com